Hui Yang1, Lihua Qiu, Wen Di, Aiming Zhao, Guangjie Chen, Ke Hu, Qide Lin. 1. Department of Obstetrics and Gynecology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China. yanghu.ya@163.com
Abstract
OBJECTIVE: To investigate the proportional changes of CD4(+)CD25(+) regulatory T cells in peripheral blood after lymphocyte therapy in unexplained recurrent spontaneous abortion (URSA) patients. DESIGN: Prospective cohort study. SETTING: University Hospital. PATIENT(S): Twenty-five URSA patients. INTERVENTION(S): Measurements of CD4(+)CD25(+) regulatory T cells in peripheral blood before and after paternal or third-party lymphocyte immunization. MAIN OUTCOME MEASURE(S): The proportion of CD4(+)CD25(bright) regulatory T cells and the percentage of CD25(bright) cells in the CD4(+) T-cell population. RESULT(S): The proportion of CD4(+)CD25(bright) T cells in peripheral blood from URSA patients was increased significantly after paternal or third-party lymphocyte immunization therapy, whereas the percentage of CD4(+)CD25(dim) cells were decreased significantly. The percentage of CD4(+)CD25(bright) cells in the CD4(+) T-cell population was significantly increased, and the proportion of CD4(+)CD25(bright) T cells was significantly higher in successfully pregnant women than in those with pregnancy loss after lymphocyte therapy. CONCLUSION(S): Allogeneic lymphocyte therapy can enhance the percentage of CD4(+)CD25(bright) regulatory T cells in peripheral blood, therefore CD4(+)CD25(+) regulatory T cells may serve as a novel biomarker for monitoring allogeneic lymphocyte therapy in URSA patients.
OBJECTIVE: To investigate the proportional changes of CD4(+)CD25(+) regulatory T cells in peripheral blood after lymphocyte therapy in unexplained recurrent spontaneous abortion (URSA) patients. DESIGN: Prospective cohort study. SETTING: University Hospital. PATIENT(S): Twenty-five URSA patients. INTERVENTION(S): Measurements of CD4(+)CD25(+) regulatory T cells in peripheral blood before and after paternal or third-party lymphocyte immunization. MAIN OUTCOME MEASURE(S): The proportion of CD4(+)CD25(bright) regulatory T cells and the percentage of CD25(bright) cells in the CD4(+) T-cell population. RESULT(S): The proportion of CD4(+)CD25(bright) T cells in peripheral blood from URSA patients was increased significantly after paternal or third-party lymphocyte immunization therapy, whereas the percentage of CD4(+)CD25(dim) cells were decreased significantly. The percentage of CD4(+)CD25(bright) cells in the CD4(+) T-cell population was significantly increased, and the proportion of CD4(+)CD25(bright) T cells was significantly higher in successfully pregnant women than in those with pregnancy loss after lymphocyte therapy. CONCLUSION(S): Allogeneic lymphocyte therapy can enhance the percentage of CD4(+)CD25(bright) regulatory T cells in peripheral blood, therefore CD4(+)CD25(+) regulatory T cells may serve as a novel biomarker for monitoring allogeneic lymphocyte therapy in URSA patients.
Authors: Ryan J Heitmann; R Patrick Weitzel; Yanling Feng; James H Segars; John F Tisdale; Erin Foran Wolff Journal: Reprod Sci Date: 2016-11-11 Impact factor: 3.060
Authors: Miriam I Wagner; Charlotte Mai; Edgar Schmitt; Karsten Mahnke; Stefan Meuer; Volker Eckstein; Anthony D Ho; Matthias Schaier; Martin Zeier; Julia Spratte; Herbert Fluhr; Andrea Steinborn Journal: Immunol Cell Biol Date: 2015-04-27 Impact factor: 5.126
Authors: M I Wagner; M Jöst; J Spratte; M Schaier; K Mahnke; S Meuer; M Zeier; A Steinborn Journal: Clin Exp Immunol Date: 2015-10-12 Impact factor: 4.330